Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey. more
Time Frame | BMY | Sector | S&P500 |
---|---|---|---|
1-Week Return | -10.31% | -0.62% | 0.86% |
1-Month Return | -16.11% | -4.12% | -2.34% |
3-Month Return | -10% | 0.26% | 4.25% |
6-Month Return | -12.26% | 14.32% | 23.68% |
1-Year Return | -33% | 6.35% | 24.66% |
3-Year Return | -21.88% | 21.28% | 28% |
5-Year Return | 11.89% | 71.51% | 88.59% |
10-Year Return | 18.34% | 183.91% | 226.28% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 26.14B | 42.52B | 46.38B | 46.16B | 45.01B | [{"date":"2019-12-31","value":56.37,"profit":true},{"date":"2020-12-31","value":91.66,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.51,"profit":true},{"date":"2023-12-31","value":97.03,"profit":true}] |
Cost of Revenue | 8.08B | 11.77B | 9.94B | 10.14B | 10.69B | [{"date":"2019-12-31","value":68.61,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":84.43,"profit":true},{"date":"2022-12-31","value":86.1,"profit":true},{"date":"2023-12-31","value":90.83,"profit":true}] |
Gross Profit | 18.07B | 30.75B | 36.45B | 36.02B | 34.31B | [{"date":"2019-12-31","value":49.57,"profit":true},{"date":"2020-12-31","value":84.36,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.84,"profit":true},{"date":"2023-12-31","value":94.15,"profit":true}] |
Gross Margin | 69.10% | 72.31% | 78.57% | 78.04% | 76.24% | [{"date":"2019-12-31","value":87.95,"profit":true},{"date":"2020-12-31","value":92.03,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.32,"profit":true},{"date":"2023-12-31","value":97.03,"profit":true}] |
Operating Expenses | 12.15B | 28.57B | 27.91B | 26.92B | 26.12B | [{"date":"2019-12-31","value":42.54,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.69,"profit":true},{"date":"2022-12-31","value":94.22,"profit":true},{"date":"2023-12-31","value":91.42,"profit":true}] |
Operating Income | 5.46B | 5.13B | 10.16B | 10.33B | 17.24B | [{"date":"2019-12-31","value":31.69,"profit":true},{"date":"2020-12-31","value":29.74,"profit":true},{"date":"2021-12-31","value":58.92,"profit":true},{"date":"2022-12-31","value":59.9,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | (1.15B) | (13.42B) | (3.40B) | (3.85B) | 267.00M | [{"date":"2019-12-31","value":-428.84,"profit":false},{"date":"2020-12-31","value":-5025.84,"profit":false},{"date":"2021-12-31","value":-1271.54,"profit":false},{"date":"2022-12-31","value":-1440.82,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | 4.97B | (6.87B) | 8.10B | 7.71B | 8.44B | [{"date":"2019-12-31","value":58.95,"profit":true},{"date":"2020-12-31","value":-81.41,"profit":false},{"date":"2021-12-31","value":95.95,"profit":true},{"date":"2022-12-31","value":91.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | 1.51B | 2.12B | 1.08B | 1.37B | 400.00M | [{"date":"2019-12-31","value":71.33,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":51.04,"profit":true},{"date":"2022-12-31","value":64.41,"profit":true},{"date":"2023-12-31","value":18.83,"profit":true}] |
Income After Taxes | 3.46B | (8.99B) | 7.01B | 6.34B | 8.04B | [{"date":"2019-12-31","value":43.03,"profit":true},{"date":"2020-12-31","value":-111.88,"profit":false},{"date":"2021-12-31","value":87.24,"profit":true},{"date":"2022-12-31","value":78.92,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Continuous Operations | 6.49B | (8.99B) | 7.01B | 6.34B | 8.30B | [{"date":"2019-12-31","value":78.16,"profit":true},{"date":"2020-12-31","value":-108.33,"profit":false},{"date":"2021-12-31","value":84.48,"profit":true},{"date":"2022-12-31","value":76.42,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 3.44B | (8.99B) | 6.99B | 6.33B | 8.03B | [{"date":"2019-12-31","value":42.85,"profit":true},{"date":"2020-12-31","value":-112.09,"profit":false},{"date":"2021-12-31","value":87.15,"profit":true},{"date":"2022-12-31","value":78.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
EPS (Diluted) | 4.67 | 6.44 | 7.50 | 7.80 | 7.50 | [{"date":"2019-12-31","value":59.87,"profit":true},{"date":"2020-12-31","value":82.56,"profit":true},{"date":"2021-12-31","value":96.15,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.15,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
BMY | |
---|---|
Cash Ratio | 0.37 |
Current Ratio | 1.11 |
Quick Ratio | 0.99 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BMY | |
---|---|
ROA (LTM) | 5.39% |
ROE (LTM) | -25.33% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BMY | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.83 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.17 |
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 6.01 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BMY | |
---|---|
Trailing PE | NM |
Forward PE | 6.93 |
P/S (TTM) | 2.17 |
P/B | 3.32 |
Price/FCF | 35 |
EV/R | 2.82 |
EV/Ebitda | 6.56 |
PEG | 0.08 |
A federal judge on Monday threw out legal challenges to the Medicare negotiation program that had been brought by Bristol Myers Squibb and Johnson & Johnson, finding that their claims of unconstitutionality do not hold up. In their two separate lawsuits, both Bristol Myers Squibb and Johnson & Johnson allege that the Medicare negotiation program…
Today, Fuel Africa 2024, a groundbreaking initiative hosted by Futurize, has successfully concluded, marking a significant milestone in integrating healthcare technology innovations with climate change solutions across the African continent. Through the collaborative efforts of AstraZeneca through the A.Catalyst Network, and co-funded by Bristol Myers Squibb, the initiative aims to tackle immediate healthcare challenges while […] The post Fuel Africa 2024: Futurize and AstraZeneca Unveil Groundbreaking HealthTech Innovations appeared first on Tech | Business | Economy .
.… In partnership with AstraZeneca through the A. Catalyst Network and co-funded by Bristol Myers Squibb, the program tackles immediate healthcare needs and long-term resilience strategies. Today, Fuel Africa 2024, a groundbreaking initiative hosted by Futurize, has successfully concluded, marking a significant milestone in integrating healthcare technology innovations with climate change solutions across the African […] The post Fuel Africa 2024: Futurize and AstraZeneca Unveil Groundbreaking Innovations for Health Tech and Environmental Sustainability appeared first on ITPulse.com.ng .
Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into a research collaboration with Bristol Myers Squibb (NYSE: BMY) to accelerate the development of Bristol Myers Squibb’s drug targets by identifying target biology for indication selection and expansion. Under the terms of the agreement, Scenic Biotech will be entitled Jetzt den vollständigen Artikel lesen
… billion takeover of Deciphera Pharmaceuticals is a " … Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which … U.S. by partner Bristol-Myers Squibb . The drug expected to … million in 2023. Ono Pharma expects Qinlock and Vimseltinib …
NEW YORK, April 30 ― A US judge yesterday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law…
The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the constitutionality of the price talks.
Bristol-Myers Squibb Company (BMY) share price today is $43.94
Yes, Indians can buy shares of Bristol-Myers Squibb Company (BMY) on Vested. To buy Bristol-Myers Squibb Company from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BMY stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Bristol-Myers Squibb Company (BMY) via the Vested app. You can start investing in Bristol-Myers Squibb Company (BMY) with a minimum investment of $1.
You can invest in shares of Bristol-Myers Squibb Company (BMY) via Vested in three simple steps:
The 52-week high price of Bristol-Myers Squibb Company (BMY) is $66.25. The 52-week low price of Bristol-Myers Squibb Company (BMY) is $44.34.
The price-to-earnings (P/E) ratio of Bristol-Myers Squibb Company (BMY) is NM
The price-to-book (P/B) ratio of Bristol-Myers Squibb Company (BMY) is 3.32
The dividend yield of Bristol-Myers Squibb Company (BMY) is 5.35%
The market capitalization of Bristol-Myers Squibb Company (BMY) is $89.07B
The stock symbol (or ticker) of Bristol-Myers Squibb Company is BMY